DGAP-News: Sangui BioTech International Inc.: Approval of blood additive appears possible, expedient and promising - Feasibility study available
(firmenpresse) - DGAP-News: Sangui BioTech International Inc. / Key word(s): Research
Update/Product Launch
Sangui BioTech International Inc.: Approval of blood additive appears
possible, expedient and promising - Feasibility study available
09.04.2013 / 14:33
---------------------------------------------------------------------
Witten/Germany - An approval of Sangui's haemoglobin hyperpolymers as a
blood additive appears possible, expedient and promising. This was attested
to by a feasibility study prepared by an expert panel of medics,
biologists, application engineers, regulatory experts and patent lawyers on
behalf of SanguiBioTech GmbH. If approved, the product could save the lives
of hundreds of thousands of people. It functions as a carrier supplying
oxygen to parts of the body which have an oxygen deficiency due to a
narrowing or blocking of the arteries (arteriosclerotic obstruction): the
main cause of stroke, heart attack etc.
Different options for financing the undertaking, initially until completion
of the preclinical studies, are being reviewed, including the procuring of
public funding.
The authors of the study conclude that Sangui's haemoglobin hyperpolymers
are superior to the approaches pursued by the pharmaceuticals sector so
far. The study is based on a wide-ranging critical literature review,
in-deep database research and opinions by renowned experts. After extensive
scrutiny, which includes competitor approaches, the study affirms the
correctness and resilience of the concepts presented by Sangui.
Accordingly, Sangui's haemoglobin hyperpolymers fulfil all the requirements
discussed to date in respect of an oxygen carrying blood additive. The
study includes a discussion of two possible indications for initial
approval: acute myocardial infarction (heart attack), on the one hand, and
ALI/ARDS, lung damages, on the other, both of which often lead to death.
Both acute emergency indications can be alleviated by introducing the blood
additive, giving patients valuable survival time until basic medical aid
can be administered. Also, the severe multiple damages to the body after
suffering such oxygen deficiency can be minimised.
After due consideration, the experts initially recommend that approval for
ALI/ARDS be sought. These indications have a mortality rate of 40 percent,
causing around 290,000 deaths in total in the USA and in the EU every year.
The authors anticipate that classification as an orphan disease, i.e. as a
disease neglected by research, may also be possible. This would fast track
the process.
In the event of success, Sangui and its potential partners would tap a
market worth billions. Even a slight one-percent market penetration would
yield a high return potential.
Sangui BioTech International, Inc. ('SGBI') is a holding company the shares
of which are being traded on the OTCQB marketplace (www.otcmarkets.com:
SGBI) and the OTC market of Hamburg-Hannover and Berlin stock exchanges.
Its purpose is to provide financing and access to the capital markets for
the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Joachim Fleing
Phone: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing(at)sangui.de
Some of the statements contained in this news release discuss future
expectations, contain projections of results of operation or financial
condition or state other 'forward-looking' information. These statements
are subject to known and unknown risks, uncertainties, and other factors
that could cause the actual results to differ materially from those
contemplated by the statements. The forward-looking information is based on
various factors and is derived using numerous assumptions. Important
factors that may cause actual results to differ from projections include,
among many others, the ability of the Company to raise sufficient capital
to meet operating requirements. Words such as 'anticipates,' 'expects,'
'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and variations of
such words and similar expressions are intended to identify such
forward-looking statements. Unless required by law, the Company undertakes
no obligation to update publicly any forward-looking statements, whether as
a result of new information, future events or otherwise.
End of financial news
---------------------------------------------------------------------
09.04.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
206476 09.04.2013
Themen in dieser Pressemitteilung:
sangui-biotech-international-inc-approval-of-blood-additive-appears-possible
expedient-and-promising
feasibility-study-available
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
" alt="First Majestic Silver: Del Toro Silver Mine Flotation Circuit Deemed Commercial
Datum: 09.04.2013 - 14:33 Uhr
Sprache: Deutsch
News-ID 247169
Anzahl Zeichen: 5907
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 374 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Sangui BioTech International Inc.: Approval of blood additive appears possible, expedient and promising - Feasibility study available"
steht unter der journalistisch-redaktionellen Verantwortung von
Sangui BioTech International Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
